✦ LIBER ✦

PNL12 COST UTILITY ANALYSIS OF INTERFERON BETA-1A (AVONEX®) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)

✍ Scribed by M Iskedjian; J Walker; T Gray; C Vicente; T Einarson; A Gehshan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PNL9 COST EFFECTIVENESS ANALYSIS OF INTE

✍ M Iskedjian; J Walker; T Gray; C Vicente; T Einarson; A Gehshan 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB

PND15 COST-UTILITY OF INTERFERON BETA-1B

✍ JP Caloyeras; C Wang; L Bauer; WC Lee; V Lanius; K Gondek 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PNR1: COST-EFFECTIVENESS AND COST-UTILIT

✍ E Orlewska; P Mierzejewski; A Czlonkowska 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

PND26 COST-UTILITY OF INTERFERON BETA-1B

✍ T Arbizu; C Piñol; V Casado 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PND8 COST-EFFECTIVENESS AND BUDGET IMPAC

✍ O Espallardo; C Crespo; C Polanco; D Nieves 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

Cost-Utility Analyses of Natalizumab Ver

✍ Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB